睿知中国医院研究地图
候选清单

正在招募淋巴瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 12 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 12

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  2. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  3. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  4. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  5. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  6. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  7. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  8. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  9. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  10. 研究中心中国医科大学附属盛京医院Shengjing Hospital of China Medical University沈阳医院页面
  11. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  12. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06219356,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002; or chimeric antigen receptor T cell therapy (CAR-T) within 3 months prior to the first dose of GLB-002.

    排除标准第 1 条

    Currently enrolled in any other investigational drug study or participation within the last 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002 (exception of participants who participated in only one investigational drug study with overall survival follow-up).

    排除标准第 2 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.

    入选标准第 5 条

  4. History of, or current active cancer other malignancy for the past 5 years, with the exception of curatively resected cancer in situ, including cervical carcinoma in situ, basal cell carcinoma of the skin, or prostate cancer in situ, etc

    排除标准第 9 条

    Participants with known active infection of hepatitis B virus (HBV) or hepatitis C virus C (HCV).

    排除标准第 12 条

    Participants with known human immunodeficiency virus (HIV) infection.

    排除标准第 13 条

  5. Pregnant or lactating women.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06219356,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures being performed.
  2. Participants is ≥18 years of age at the time of signing the ICF.
  3. Participants with histopathologically or immunohistochemically confirmed NHL according to 2016 World Health Organization (WHO) haematolymphoid tumors criteria classification (CLL/SLL diagnosis according to 2018 IWCLL) who have failed standard of care therapy or lack an effective treatment regimen.
  4. Participants in Phase Ib screening period with measurable lesion, but no measurable nodal lesion limit for participants in Phase Ia.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
  6. Life expectancy > 3 months.
  7. Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.
  8. Participants are willing and able to adhere to the study visit schedule and other protocol requirements.

排除标准:Exclusion Criteria:

  1. Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002; or chimeric antigen receptor T cell therapy (CAR-T) within 3 months prior to the first dose of GLB-002.
  2. Currently enrolled in any other investigational drug study or participation within the last 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002 (exception of participants who participated in only one investigational drug study with overall survival follow-up).
  3. Participants with unresolved clinically significant toxicities of > Grade 1 AE or not be recovered to baseline value from prior anticancer therapies with exception of alopecia or hyperpigmentation of the skin.
  4. Participants who are scheduled to receive other anticancer therapies or other investigational drugs during the study period.
  5. Participants with active acute or chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy, or participants requiring treatment with systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 7 days prior to the first dose of GLB-002 or during the study period.
  6. Receipt of Autologous Stem Cell Transplantation (ASCT) within the last 3 months, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6 months prior to the first dose of GLB-002.
  7. Participants with known active leukemic involvement in central nervous system (CNS).
  8. Participants with peripheral neuropathy ≥ Grade 2 (Graded according to CTCAE version 5.0).
  9. History of, or current active cancer other malignancy for the past 5 years, with the exception of curatively resected cancer in situ, including cervical carcinoma in situ, basal cell carcinoma of the skin, or prostate cancer in situ, etc
  10. QT interval interval >470 milliseconds (ms) using electrocardiographic (ECG) at Screening.
  11. Participants has impaired cardiac function or clinically significant cardiac disease at current or within last 6 months.
  12. Participants with known active infection of hepatitis B virus (HBV) or hepatitis C virus C (HCV).
  13. Participants with known human immunodeficiency virus (HIV) infection.
  14. Participants with known life-threatening or clinical significant uncontrolled active systemic infections unrelated to malignant hematologic diseases
  15. Participants with a condition that may affects the absorption, distribution, metabolism and excretion of GLB-002.
  16. Medications or supplements that are known to be strong and moderate inhibitors or inducers of cytochrome P-450 isozyme (CYP)3A4/5 and/or P-glycoprotein (P-gp) within 7 days or 5 half-lives prior to the first dose of GLB-002, whichever is shorter.
  17. Participants who have undergone major surgery within 28 days prior to the first dose of the GLB-002.
  18. Pregnant or lactating women.
  19. Participants who have cognitive impairment due to any psychiatric or neurological condition, including epilepsy and dementia, may limit their understanding, performance, and study compliance with the ICF.
  20. Participants,in the opinion of the Investigator, who are unsuitable to participate in the study.

引自 ClinicalTrials.gov, NCT06219356, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06219356,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06219356